非小细胞肺癌的规范化治疗幻灯片1.pptVIP

非小细胞肺癌的规范性治疗;肺癌;UICC肺癌TNM分期(1997);UICC/AJCC肺癌分期（1997年）;非小细胞肺癌的生存率率;初始评价和临床分期（ NSCL-1 ）;检查 ;纵隔淋巴结的评价（CT 、 PET 、纵隔镜）;手术切除原则;肺癌手术性质;非小细胞肺癌辅助化疗的疗效;非小细胞肺癌完全切除术后放射治疗;需要术后放疗的高危人群;不完全性切除术后的局部晚期NSCLC治疗;Ⅰ期 （ⅠA ：T1N0M0； ⅠB：T2N0M0） Ⅱ期（ⅡA：T1N1M0； ⅡB：T2N1M0 ）;Ⅱ期(ⅡB: T3N0M0 ，侵犯胸壁或靠近隆突）;Ⅲ期（ⅢA：T1-3N2M0）;Ⅲ期NSCLC联合化放疗的研究;Ⅲ期（ⅢB：T4N0-1M0）;Ⅳ期NSCLC的治疗;STANDARD THERAPY OF NSCLC;Reasons for inoperability in patients with lung cancer;CHEMOTHERAPY OF NSCLC;对NSCLC有效的化疗药物;单药对NSCLC的疗效(90年代) ;对NSCLC有效的新药;新药单药对NSCLC的疗效;Supportive CareversusSupportive Care+Chemotherapy; Improves survival versus BSC Median, 2 mo 1-yr, 10% Hazard Rate Reduction of 26% Relieves symptoms: 66%–78% in stage III/IV Improves QOL Cost-effective;Taxanes vs BSC in Unteated Advanced NSCLC;IV期NSCLC随机临床试验;治疗后复发和转移的再处理;NSCLC联合化疗方案(1);NSCLC联合化疗方案(2);NSCLC联合化疗方案(3);NSCLC联合化疗方案(4);NSCLC联合化疗方案(5);Cumulative Phase II Data of New Drugs Combined with Platinum; R A N D O M I Z E; TC GC TxC TCb N 288 288 289 290 Median Age 62 64 63 63 % PS2 6% 5% 6% 5% % Stage IV 89% 86% 86% 86% ORR (%) 21% 22% 17% 17% TTP (m) 3.4 4.2* 3.7 3.1 MST (m) 7.8 8.1 7.4 8.1 1-yr Survival 31% 36% 31% 34% 2-yr survival (%) 10% 13% 11% 11% ; TC GC TxC TCb Neutropenia 18/57 24/39 21/48 20/43 Thrombocytopenia 4/2 22/28 2/1 8/2 Anemia 12/1 27/1 13/2 9/1 Febrile neutropenia 2/14 1/3 1/10 0/4 Bleeding 1/0 2/0 0/0 1/0 Vomiting 3/21 7/28 3/18 2/6 Neuropathy 5/0 9/0 5/0 10/0 Hypersensitivity 2/1 0/0 5/2 1/1 Renal 3/0 6/